CJC-1295 & Hexarelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

CJC-1295 & Hexarelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Potent synthetic hexapeptide GHS-R1a / CD36 dual agonist that stimulates GH release and exerts direct cardioprotective effects; research use only.

Hexarelin acts as a high-affinity agonist at GHS-R1a (the ghrelin receptor), a Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic arcuate neurons. Binding activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone while simultaneously potentiating endogenous GHRH signalling and partially suppressing somatostatin tone. Hexarelin also activates the ERK1/2 (MAPK) pathway downstream of PKC and GHS-R1a engagement, contributing to proliferative and cytoprotective signalling in non-pituitary tissues. A second pharmacological target, the cardiac scavenger receptor CD36, mediates direct cardioprotective effects — including positive inotropy, reduction of cardiomyocyte apoptosis following ischaemia–reperfusion injury, and modulation of coronary microvascular tone — independently of GH secretion. Because hexarelin is among the highest-affinity synthetic GHRPs, prolonged or repeated dosing produces faster and more complete GHS-R1a desensitisation than lower-affinity secretagogues such as ipamorelin.

Molar mass

887.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. — COMPONENT-LEVEL, NOT BLEND-LEVEL. Two randomized, placebo-controlled, double-blind ascending-dose human trials of CJC-1295 MONOTHERAPY (the long-acting DAC/albumin-binding form, t½ 5.8-8.1 d) in healthy adults — the sole completed, results-published human RCT among either component. NOTE: this is CJC-1295-DAC, a DIFFERENT molecular entity from the short-acting no-DAC ('Mod GRF 1-29') CJC-1295 the vendors of this blend actually sell. Does not evaluate hexarelin or the combination; does NOT count toward the blend's completedHumanRcts (0).
• A Study to Evaluate CJC-1295 in HIV Patients With Visceral Obesity (ClinicalTrials.gov NCT00267527) — Phase 2, randomized, placebo-controlled; sponsor ConjuChem. Intervention listed solely as CJC-1295 (no hexarelin). — COMPONENT-LEVEL, NOT BLEND-LEVEL. Per the primary CTgov record: CJC-1295-only Phase 2 trial in HIV-associated visceral adiposity, overallStatus TERMINATED, hasResults=false. It is NOT a completed RCT and NOT an efficacy result. The associated serious adverse event (a participant died of an acute myocardial infarction ~hours after an injection; ConjuChem halted the trial 2006-07-17) is documented not by CTgov but by independent reporting (aidsmap/NAM, https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death); a later ConjuChem statement reported the attending physician judged the death likely due to pre-existing asymptomatic coronary artery disease and UNRELATED to CJC-1295, with the trial stopped as a precaution. Framed strictly as an adverse event with investigator-assessed 'unrelated' causality — never as CJC-1295 causing a death, never blend-attributed.
• Giustina A, et al. (human hexarelin GH-secretion study, J Endocrinol 1995. PMID 7561633). Corroborating cite for hexarelin's component-level human data — Brescia group, NOT Ghigo/Arvat. True Ghigo/Arvat Turin-group human hexarelin studies: PMID 7962341 (JCEM 1994), PMID 7731498 (Neuroendocrinology 1995). — COMPONENT-LEVEL, NOT BLEND-LEVEL. Hexarelin has a decades-deep completed-human dose-response/endocrine study base (Italian endocrinology groups, 1990s-2000s) as a standalone GH secretagogue. None of these studies test hexarelin combined with CJC-1295. CJC-1295's earliest human data is 2006 (Teichman), so the 1990s hexarelin literature cannot and does not test the blend.
• Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. PMID 25278975. — COMPONENT-LEVEL, NOT BLEND-LEVEL. Review of hexarelin's GH-independent cardioprotective action via the cardiac CD36 receptor, synthesizing human + animal cardiovascular data for hexarelin ALONE. No blend-level cardiovascular data exists.
• Dominikowski J, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026. PMID 42395176. — COMPONENT-/CATEGORY-LEVEL, NOT BLEND-LEVEL. 2026 narrative Review discussing CJC-1295 (GHRH analog) and hexarelin (GH secretagogue) as SEPARATE compound categories — the closest the literature comes to co-mentioning both. It does not name, study, or evaluate the CJC-1295+Hexarelin blend as a combined product.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) — the exclusively marketed and reconstituted route for this blend product; every vendor product page surveyed sells it as a lyophilized powder (combined vial or paired two-vial kit) for SC injection, none as oral/nasal/topical. No formal pharmacokinetic study of the combined CJC-1295 + Hexarelin blend as a single unit exists at any route — the PK data below are COMPONENT-level only. Honesty flag: the CJC-1295 sold in this blend is consistently the short-acting no-DAC ('Mod GRF 1-29') form per vendor labeling, a materially different molecule/PK profile from the long-acting DAC-conjugated CJC-1295 studied in Teichman et al. 2006 (the only controlled human RCT for either component's SC route). PubMed searches for the named blend as a combined product return no dedicated trials or PK studies — see the evidence section (component science lives on the cjc-1295 and hexarelin datasheets).

No formal PK study of the CJC-1295 & Hexarelin blend as a combined product exists. Component-level, not blend-level: Hexarelin's SC pharmacology was characterized in a human dose-response study (12 healthy adults, 1.5 and 3 µg/kg — Ghigo et al. 1994) and in Sprague-Dawley rats (5/10/50 µg/kg — Roumi et al. 2000). CJC-1295 WITH DAC's SC pharmacology was characterized in a randomized, double-blind, placebo-controlled human dose-escalation trial (Teichman et al. 2006, 30-120 µg/kg, n=21). Formulation caveat: every vendor page surveyed for this blend sells CJC-1295 WITHOUT DAC ('Mod GRF 1-29', short-acting) paired with Hexarelin — not the long-acting DAC form the Teichman RCT tested. No dedicated published human or animal PK study of CJC-1295 without DAC was identified.

Bioavailability: Hexarelin SC bioavailability measured at 77.0% ± 10.5% relative to IV in humans (Ghigo et al. 1994) and 64% in rats (Roumi et al. 2000; SC elimination t½ ~75.9 min by the IV reference route). No published bioavailability or half-life figure exists for CJC-1295 without DAC via any route from a peer-reviewed source; vendor/marketing material (NOT a primary study, Layer B) describes an approximate 30-min half-life for the no-DAC form, versus the 5.8-8.1-day half-life established for the DAC-conjugated form in Teichman et al. 2006 — a materially different PK profile from a different product.

The dominant route as marketed: every vendor page surveyed lists this blend as a sterile lyophilized powder (single combined vial or paired two-vial kit) reconstituted for subcutaneous injection — a commerce/format fact, not a human dosing protocol. Evidence is component-level only; no blend-specific PK or efficacy study was found.

Component-level, not blend-level: Hexarelin IV dose-response was characterized in humans (1 and 2 µg/kg bolus, 12 healthy adults — Ghigo et al. 1994) and used as the 100%-bioavailability reference route in rats (5 µg/kg bolus — Roumi et al. 2000). No IV PK study of CJC-1295 (DAC or no-DAC) in any species was identified; the Teichman et al. 2006 human trial used SC dosing only. No blend-level IV study exists.

Bioavailability: IV defines the 100% reference bioavailability point for Hexarelin PK comparisons; elimination t½ ~75.9 ± 9.3 min in rats (Roumi et al. 2000). No IV PK data exist for CJC-1295 in either formulation.

A laboratory/clinical pharmacology reference route used to characterize the Hexarelin component's kinetics — not how this blend product is marketed or reconstituted (every vendor surveyed lists an SC-injection lyophilized vial, not an IV product). No human-dosing protocol implied.

Component-level, not blend-level: Hexarelin intranasal GH-releasing activity was studied in healthy adults (20 µg/kg — Ghigo et al. 1994) and, separately, in a small open-label clinical trial of 8 prepubertal short-statured children (ages 4-11.6; 60 µg/kg three times daily for up to 8 months — Laron et al. 1995, Clin Endocrinol). No intranasal study of CJC-1295 (either form) or of the combined blend was identified.

Bioavailability: Intranasal relative bioavailability measured at 4.8% ± 0.9% vs IV in adults (Ghigo et al. 1994). No CJC-1295 or blend-level intranasal PK data exist.

Hexarelin-component-only clinical literature, including a small open-label growth-velocity trial in minors (Laron et al. 1995, n=8; PubMed pubtype 'Clinical Trial'); reported PURELY as historical published research under RUO — what was studied in the literature, never a usage protocol, dosing recommendation, or efficacy/benefit claim. This blend product is not sold or marketed in a nasal-spray format by any vendor surveyed.

Component-level, not blend-level: Hexarelin oral GH-releasing activity was studied in humans (20 and 40 mg oral — Ghigo et al. 1994), and its poor oral absorption mechanism was characterized via rat intestinal-content and hepatic first-pass studies (Westberg et al. 2001, J Pharm Pharmacol). No oral study of CJC-1295 (either form) or of the combined blend was identified.

Bioavailability: Oral bioavailability measured at only 0.3% ± 0.1% relative to IV in humans (Ghigo et al. 1994; confirmed Westberg et al. 2001), attributed to pancreatic-protease/trypsin degradation in gut contents — the metabolite identified as hexarelin deamidated at the lysine residue (Westberg et al. 2001, rat intestinal model) — plus hepatic first-pass extraction. No CJC-1295 oral bioavailability figure has been published for either formulation.

Documents a severe oral-absorption limitation for the Hexarelin component; this is NOT evidence of oral efficacy, safety, or a human oral-use protocol. No vendor surveyed sells an oral capsule/tablet format of this blend — every listing is an injectable lyophilized vial.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

p25 $6.29 · median $8.70 · p75 $9.14 · 7 researched vendors

Legit, COA-backed band: $5.37–$10.81/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$12

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

No independent lab issues a single purity % for a two-peptide blend vial: a combined-peptide sample can only have each component's identity and mass confirmed, not one overall purity percentage, because HPLC/LC-MS cannot attribute which peaks belong to which of two intentional peptides. Component-level, not blend-level: Finnrick's CJC-1295 aggregate (204 samples across 41 US vendors, 17 Dec 2024 - 6 Jan 2026) found purity ranging 1.69%-100.00% with advertised quantity diverging up to ±100% vs label; individual Janoshik-verified CJC-1295 batches from reputable single-peptide vendors commonly report ~99-99.7% HPLC purity. No comparable independent purity aggregate was found for Hexarelin alone or for the blend as sold.

Independent labs cited for this compound

No recall of a 'CJC-1295 & Hexarelin' blend product specifically was found. The one confirmed CJC-1295-linked FDA recall (Thrive Health Solutions, May-June 2025, Class II, sterility — see events) concerns a licensed-pharmacy compounded single-peptide injectable, NOT a research-market CJC-1295/Hexarelin blend vial. No Hexarelin-specific recall was found. Reported as an honest 'none found' result for the blend itself — not invented.

Buyer red-flag checklist

• Vendor cannot produce a batch-specific, independently verifiable Janoshik/lab task ID for the blend — for a genuine two-component product, expect per-component mass/identity data, not a single vague 'blend purity' number.
• A single combined 'blend purity %' claim (e.g. '99% purity') with no per-peptide HPLC/LC-MS breakdown — an accepted analytical limitation means a real independent lab cannot issue one figure for a true two-peptide blend.
• Ambiguous DAC labeling: CJC-1295 exists in DAC and no-DAC forms with very different half-lives; a vendor that doesn't clearly disclose which form is in the blend has failed basic disclosure.
• Price far below the market's per-mg-of-each-component norm — a community-documented pattern is cheaper sermorelin substituted for CJC-1295, since HPLC alone can't reliably distinguish the two GHRH analogs without mass spec.
• No endotoxin (LAL) or sterility data offered for a product sold as a reconstitutable, injectable lyophilized powder.
• Cryptocurrency-only payment, no verifiable company address/email domain, or no return/reship policy.
• Human-dosing / benefit marketing ('anti-aging', 'muscle-growth protocol') on a site labeled 'research use only' — the same marketing pattern that has drawn FDA and Health Canada enforcement against research-peptide sellers generally.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No aggregate independent-lab study quantifies underdosing/mislabeling prevalence for the 'CJC-1295 & Hexarelin' blend specifically, or for Hexarelin alone — honest null, not estimated. Finnrick's CJC-1295 aggregate (component-level, not blend-level) shows advertised quantity diverging by up to ±100% across 204 samples/41 vendors, directionally consistent with the underdosing risk documented across the research-peptide market generally, but not a clean single blend-level prevalence figure. Community-documented substitution risk (component-level, unverified for this specific blend): vendors have reportedly substituted cheaper sermorelin for CJC-1295 — both are GHRH analogs, and HPLC alone does not reliably distinguish them without mass spec.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') is a real standing alert, and it does NOT individually name CJC-1295 or Hexarelin (verified: 0 occurrences across the alert's Red List, though related GH-secretagogue peptides such as Ipamorelin, GHRP-2, GHRP-6, Somatropin and Melanotan do appear). Both CJC-1295 and Hexarelin are unapproved new drugs with no FDA-approved human indication, so FDA can detain such peptide imports under 66-41's unapproved-new-drug CLASS basis — but do not attribute a specific 66-41 listing to these two substances. The FDA instrument that actually names CJC-1295 is the 503A interim bulk-substances mechanism (see events/regulatory), a distinct pathway from border DWPE. An RUO label is not an import exemption; FDA judges actual promoted/intended use.66-41 (class basis only — CJC-1295/Hexarelin not individually named)
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Neither CJC-1295 nor hexarelin is a named substance on the WADA Prohibited List as a 'blend' — the blend itself has no independent WADA listing — but BOTH individual components are prohibited AT ALL TIMES (in- and out-of-competition) under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically subsection S2.2.4 'Growth hormone releasing factors' on the WADA 2026 Prohibited List (effective 1 Jan 2026). CJC-1295 (with CJC-1293, sermorelin, tesamorelin) is listed as a GHRH analogue; examorelin (hexarelin) is listed among the GH-releasing peptides (GHRPs, alongside alexamorelin, GHRP-1 through GHRP-6/pralmorelin). This is a component-level anti-doping classification (WADA schedules substances, not blends); both are non-specified substances carrying strict-liability, four-year-default sanctions.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Identifiable discourse specific to the NAMED CJC-1295+Hexarelin blend (vs the individual components generally) is thin; most secondary community signal sits on bodybuilding/TRT/'heightmaxing' forums (ExcelMale, IronMagazineForums, Looksmax.org, ProfessionalMuscle) OUTSIDE the tracked platform set (reddit/bluesky/youtube/x) — read this sample as a small, secondary-reported cross-section, not a comprehensive discourse read
• The single most load-bearing Reddit-reception data point (an r/Peptides thread reportedly calling the stack 'probably the worst stack you could've chosen') is known only via a SECONDARY aggregator account (Looksmax.org), not a directly-reviewed original thread — treat as illustrative, NOT a quantified sentiment count. [Verification: non-refuted but secondary-sourced; a human should confirm the aggregator did not fabricate/misattribute the reaction before this is relied upon.]
• counterfeitChatter ('med') is grounded partly in a genuine Layer-A regulatory signal — the CPSA/Health Canada advisories name CJC-1295 and Hexarelin (individually, COMPONENT-level, not this blend SKU) among unauthorized/counterfeit injectable peptides — plus a documented blend-verification-difficulty pattern for CJC-1295-containing blends; it is NOT a claim that this specific vendor roster has been defrauded
• Vendor product-page copy ('lean mass gains', 'tissue regeneration') is commercially interested and was excluded from the sentiment read where distinguishable from independent discussion
• Anecdotal self-reports (single detailed cycle logs) lack dosing controls, blinding, or medical supervision and cannot be generalized
• Hexarelin/CJC-1295-specific discourse is heavily commingled with other GHRP-family stacks (GHRP-2, GHRP-6, ipamorelin, MK-677), diluting blend-specific signal
• Hexarelin's appetite-stimulation profile is inconsistently reported across sources (some describe no meaningful ghrelin-driven hunger increase vs GHRP-6, others list 'increased appetite' generically) — held out of reportedConcerns as unresolved rather than asserted either way

Manually researched from reddit— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research blend combining the GHRH analog CJC-1295 (Mod GRF 1-29) with the growth-hormone secretagogue hexarelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet